Abstract
Advances in viral nucleic acid amplification and detection techniques have resulted in molecular diagnostics becoming key procedures in viral infection characterization. Molecular assay development applied to clinical diagnostic and transfusion safety is essentially limited by cost. To overcome this limitation, multiplex nucleic acid testing (NAT) assays allowing simultaneous detection and eventually direct identification of several viral genomes have been developed using recent technical improvements in genomic amplification technologies. Optimization may prove difficult, but commercial and in-house multiplex NAT assays have been successfully applied to large-scale screening of blood donations for HBV, HCV and HIV-1, improving transfusion safety by reducing the pre-seroconversion window period. They showed high sensitivity and specificity, and may decrease operating costs and testing turnaround time. Multiplexing has the potential to improve blood safety in highly endemic resource-limited areas in a cost-effective way when associated with other costreducing procedures such as plasma pooling and pre-donation serological screening.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
